Two-decade change in prevalence of cognitive impairment in the UK.


Journal

European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 17 12 2018
accepted: 21 08 2019
pubmed: 7 9 2019
medline: 10 4 2020
entrez: 7 9 2019
Statut: ppublish

Résumé

Identification of individuals at high risk of dementia has usually focused attention on the clinical concept of mild cognitive impairment (MCI), which captures an intermediate state between normal cognitive ageing and dementia. In many countries age specific risk of dementia has declined, but whether this is also the case for subclinical cognitive impairment is unknown. This has important implications for prevention, planning and policy. Here we describe subclinical cognitive impairment and mild dementia prevalence changes, in the UK, over 2 decades. The Cognitive Function and Ageing Studies have examined the full spectrum of cognition, from normal to dementia, in representative populations of people aged ≥ 65 years in the UK over the last 2 decades 7635 participants were interviewed in CFAS I in Cambridgeshire, Newcastle, and Nottingham in 1991, with 1457 being diagnostically assessed. In the same geographical areas, the CFAS II investigators interviewed 7796 individuals in 2011. Using established criteria, the population was categorised into seven groups: no cognitive impairment, Mild cognitive Impairment (defined using consensus criteria), other cognitive impairment no dementia without functional impairment, OCIND with functional impairment, cognitive impairment (MMSE < 24 and no functional impairment), mild dementia (MMSE < 24 with functional impairment, not captured by CFAS dementia criteria), and CFAS dementia criteria. Multinomial logistic regression, adjusted for age and sex, was used to estimate the prevalence of impairment in both studies. Results were standardized to the age-sex specific UK and global population. There is a clear increase in the prevalence of other cognitive Impairment no Dementia (without functional impairment), with the purer MCI remaining stable. In the UK, mild dementia is estimated to fall from 520,704 cases (5.7%, 95% CI 3.8, 8.1) in 1991 to 315,142 (3.0%, 95% CI 2.4, 3.8) in 2011, cognitive impairment, has fallen from 1,225,984 (13.5%, 95% CI 10.1, 17.5) to 654,436 (6.3%, 95% CI 5.4, 7.3) cases. Using additional categories which reflect the continuum of cognitive decline and impairment in populations we see that the mildest dementia declines, but that there is stability in estimates of those who meet MCI criteria. Increases were found in the Other Cognitive Impairment no Dementia group. The decline observed in severe impairment thus seems to have resulted in larger proportions of the population in milder forms, seen alongside physical illnesses.

Identifiants

pubmed: 31489532
doi: 10.1007/s10654-019-00554-x
pii: 10.1007/s10654-019-00554-x
pmc: PMC6861197
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1085-1092

Subventions

Organisme : Medical Research Council
ID : G0400077
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0601022
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9901400
Pays : United Kingdom
Organisme : Alzheimer's Society UK
ID : NK

Références

J Alzheimers Dis. 2018;66(2):653-680
pubmed: 30347617
Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):404-18
pubmed: 27042901
Neurology. 2001 Jan 9;56(1):37-42
pubmed: 11148233
Alzheimers Dement. 2009 May;5(3):227-33
pubmed: 19426950
Age Ageing. 1995 Sep;24(5):375-81
pubmed: 8669338
J Int Neuropsychol Soc. 2011 Mar;17(2):277-88
pubmed: 21205413
PLoS One. 2015 Nov 05;10(11):e0142388
pubmed: 26539987
Alzheimers Res Ther. 2013 Sep 06;5(5):43
pubmed: 24010759
J Am Geriatr Soc. 2008 Aug;56(8):1424-33
pubmed: 18662209
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Neurology. 2006 Dec 26;67(12):2176-85
pubmed: 17190940
BMJ. 2013 Sep 09;347:f5125
pubmed: 24018000
JAMA Intern Med. 2017 Jan 1;177(1):51-58
pubmed: 27893041
Arch Neurol. 2003 Oct;60(10):1385-9
pubmed: 14568808
J Intern Med. 2014 Mar;275(3):214-28
pubmed: 24605806
Arch Neurol. 2010 Jan;67(1):80-6
pubmed: 20065133
Lancet Neurol. 2008 Feb;7(2):161-72
pubmed: 18207114
Am J Geriatr Psychiatry. 2017 Apr;25(4):328-339
pubmed: 27618647
Dement Geriatr Cogn Disord. 2005;19(2-3):113-9
pubmed: 15591801
Lancet. 2013 Oct 26;382(9902):1405-12
pubmed: 23871492
Ann Neurol. 2008 Apr;63(4):494-506
pubmed: 18300306
Am J Geriatr Psychiatry. 2010 Aug;18(8):674-83
pubmed: 20220597
Lancet. 2012 Oct 20;380(9851):1441-3
pubmed: 23084456
Neurology. 2007 May 29;68(22):1909-16
pubmed: 17536047
Alzheimers Dement. 2012 Jan;8(1):14-21
pubmed: 22265588
Age Ageing. 2011 Jul;40(4):501-7
pubmed: 21673136
J Am Geriatr Soc. 2007 Oct;55(10):1534-40
pubmed: 17908056
Arch Neurol. 2011 Jun;68(6):761-7
pubmed: 21670400
Alzheimers Dement. 2011 Jan;7(1):80-93
pubmed: 21255746
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
Int J Geriatr Psychiatry. 2008 Aug;23(8):863-71
pubmed: 18537198
Br J Psychiatry. 1986 Dec;149:698-709
pubmed: 3790869
Nat Commun. 2016 Apr 19;7:11398
pubmed: 27092707

Auteurs

Connor Richardson (C)

Newcastle University Institute for Ageing and Institute for Health and Society, Newcastle University, Newcastle Biomedical Research Building, Newcastle upon Tyne, NE4 5PL, UK.

Blossom C M Stephan (BCM)

Division of Psychiatry and Applied Psychology, Institute of Mental Health, School of Medicine, University of Nottingham, Innovation Park, Nottingham, NG7 2TU, UK.

Louise Robinson (L)

Newcastle University Institute for Ageing and Institute for Health and Society, Newcastle University, Newcastle Biomedical Research Building, Newcastle upon Tyne, NE4 5PL, UK.

Carol Brayne (C)

Cambridge Institute of Public Health, University of Cambridge School of Clinical Medicine, Forvie Site, Cambridge Biomedical Campus, Cambridge, CB2 0SR, UK.

Fiona E Matthews (FE)

Newcastle University Institute for Ageing and Institute for Health and Society, Newcastle University, Newcastle Biomedical Research Building, Newcastle upon Tyne, NE4 5PL, UK. Fiona.Matthews@newcastle.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH